Eris Lifesciences Intrinsic Value
ERIS • Healthcare
Current Stock Price
₹1332.10
Primary Intrinsic Value
₹776.16
Market Cap
₹1865 Cr
+100.0%
Upside
Median Value
₹2664.20
Value Range
₹400 - ₹3330
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
ERIS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹776.16 | ₹620.93 - ₹931.39 | -41.7% | EPS: ₹35.28, Sector P/E: 22x |
| Book Value Method | asset | ₹3330.25 | ₹2997.22 - ₹3663.28 | +150.0% | Book Value/Share: ₹2337.14, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2664.20 | ₹2397.78 - ₹2930.62 | +100.0% | Revenue/Share: ₹2265.71, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2664.20 | ₹2397.78 - ₹2930.62 | +100.0% | EBITDA: ₹1156.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹3330.25 | ₹2664.20 - ₹3996.30 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹399.63 | ₹359.67 - ₹439.59 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹545.08 | ₹490.57 - ₹599.59 | -59.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2664.20 | ₹2397.78 - ₹2930.62 | +100.0% | ROE: 16.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1362.07 | ₹1225.86 - ₹1498.28 | +2.2% | EPS: ₹35.28, BVPS: ₹2337.14 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
ERIS Intrinsic Value Analysis
What is the intrinsic value of ERIS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Eris Lifesciences (ERIS) is ₹2664.20 (median value). With the current market price of ₹1332.10, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹399.63 to ₹3330.25, indicating ₹399.63 - ₹3330.25.
Is ERIS undervalued or overvalued?
Based on our multi-method analysis, Eris Lifesciences (ERIS) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.51 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 16.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.45x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Eris Lifesciences
Additional stock information and data for ERIS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,065 Cr | ₹1,026 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹486 Cr | ₹-428 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹292 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹378 Cr | ₹218 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹375 Cr | ₹214 Cr | Positive Free Cash Flow | 8/10 |